(ETX)25 Jun 2019 11:50
What analysts are saying
“In the current challenging financing environment for UK-based life science companies, ETX is firstly conserving resources,” said research house Edison.
“FY19 was the latest in a three-year trend of sequentially declining six-monthly losses and the lowest half-yearly loss since 2012.
“In addition, a range of partnering activities are being explored. These two facets come together with the metered investment in the self-funded NDD-derived assets, the board exploring alternative sources of capital that could include non-dilutive funding and also potentially the earlier partnering and cost-sharing for assets and partnerships that may reduce the long-term upside to ETX, but enable nearer-term value creation.”